AIM ImmunoTech Reports Q2 Losses Amid Ongoing Trials, Revenue Down to $25k.
ByAinvest
Friday, Aug 15, 2025 7:26 pm ET1min read
AIM--
AIM ImmunoTech Inc. reported a decrease in total revenues to $25,000 from $50,000 YoY and a net loss of $2.8 million, up from $1.8 million in the previous year. The company is focused on clinical trials for Ampligen in treating pancreatic cancer and exploring its antiviral properties. Despite financial challenges, AIM ImmunoTech remains committed to advancing its research and development efforts. Management expresses optimism about future clinical trials and potential regulatory approvals.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet